Relative Effectiveness of MF59 Adjuvanted Trivalent Influenza Vaccine vs Nonadjuvanted Vaccines During the 2019-2020 Influenza Season.
Author
Imran, MahrukhPuig-Barbera, Joan
Ortiz, Justin R
Fischer, Lauren
O'Brien, Dan
Bonafede, Machaon
Mansi, James A
Boikos, Constantina
Date
2022-04-02Journal
Open Forum Infectious DiseasesPublisher
Oxford University PressType
Article
Metadata
Show full item recordAbstract
This retrospective cohort study used electronic medical records linked to pharmacy and medical claims data. The study population included adults age ≥65 years with a record of aIIV3, IIV4e, or HD-IIV3 vaccination. A doubly robust inverse probability of treatment weighting model was used to derive adjusted odds ratios (ORs). rVE was calculated by (1 - ORadjusted)*100 and was determined overall and separately for age subgroups. An exploratory analysis evaluated the outcome separately in inpatient and outpatient settings.Rights/Terms
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.Keyword
adjuvanted influenza vaccinehigh-dose influenza vaccine
older adults
quadrivalent inactivated influenza vaccine
relative vaccine effectiveness
Identifier to cite or link to this item
http://hdl.handle.net/10713/18728ae974a485f413a2113503eed53cd6c53
10.1093/ofid/ofac167
Scopus Count
Collections
Related articles
- Relative Effectiveness of Adjuvanted Trivalent Inactivated Influenza Vaccine Versus Egg-derived Quadrivalent Inactivated Influenza Vaccines and High-dose Trivalent Influenza Vaccine in Preventing Influenza-related Medical Encounters in US Adults ≥ 65 Years During the 2017-2018 and 2018-2019 Influenza Seasons.
- Authors: Boikos C, Fischer L, O'Brien D, Vasey J, Sylvester GC, Mansi JA
- Issue date: 2021 Sep 7
- Effectiveness of the Adjuvanted Influenza Vaccine in Older Adults at High Risk of Influenza Complications.
- Authors: Boikos C, Imran M, Nguyen VH, Ducruet T, Sylvester GC, Mansi JA
- Issue date: 2021 Aug 5
- Comparative effectiveness of high dose versus adjuvanted influenza vaccine: A retrospective cohort study.
- Authors: van Aalst R, Gravenstein S, Mor V, Mahmud SM, Wilschut J, Postma M, Chit A
- Issue date: 2020 Jan 10
- Comparative Effectiveness of Influenza Vaccines Among US Medicare Beneficiaries Ages 65 Years and Older During the 2019-2020 Season.
- Authors: Izurieta HS, Lu M, Kelman J, Lu Y, Lindaas A, Loc J, Pratt D, Wei Y, Chillarige Y, Wernecke M, MaCurdy TE, Forshee R
- Issue date: 2021 Dec 6
- Safety, Reactogenicity, and Health-Related Quality of Life After Trivalent Adjuvanted vs Trivalent High-Dose Inactivated Influenza Vaccines in Older Adults: A Randomized Clinical Trial.
- Authors: Schmader KE, Liu CK, Harrington T, Rountree W, Auerbach H, Walter EB, Barnett ED, Schlaudecker EP, Todd CA, Poniewierski M, Staat MA, Wodi P, Broder KR
- Issue date: 2021 Jan 4
Related items
Showing items related by title, author, creator and subject.
-
Review of Analyses Estimating Relative Vaccine Effectiveness of Cell-Based Quadrivalent Influenza Vaccine in Three Consecutive US Influenza Seasons.Boikos, Constantina; McGovern, Ian; Molrine, Deborah; Ortiz, Justin R; Puig-Barberà, Joan; Haag, Mendel (MDPI AG, 2022-06-03)The adaptation of influenza seed viruses in egg culture can result in a variable antigenic vaccine match each season. The cell-based quadrivalent inactivated influenza vaccine (IIV4c) contains viruses grown in mammalian cell lines rather than eggs. IIV4c is not subject to egg-adaptive changes and therefore may offer improved protection relative to egg-based vaccines, depending on the degree of match with circulating influenza viruses. We summarize the relative vaccine effectiveness (rVE) of IIV4c versus egg-based quadrivalent influenza vaccines (IIV4e) to prevent influenza-related medical encounters (IRMEs) from three retrospective observational cohort studies conducted during the 2017-2018, 2018-2019, and 2019-2020 US influenza seasons using the same underlying electronic medical record dataset for all three seasons-with the addition of linked medical claims for the latter two seasons. We identified IRMEs using diagnostic codes specific to influenza disease (ICD J09*-J11*) from the records of over 10 million people. We estimated rVE using propensity score methods adjusting for age, sex, race, ethnicity, geographic location, week of vaccination, and health status. Subgroup analyses included specific age groups. IIV4c consistently had higher relative effectiveness than IIV4e across all seasons assessed, which were characterized by different dominant circulating strains and variable antigenic drift or egg adaptation.
-
Global influenza seasonality to inform country-level vaccine programs: An analysis of WHO FluNet influenza surveillance data between 2011 and 2016Newman, Laura (Laura P.), 1983-; Bhat, Niranjan; Fleming, Jessica Ann; Neuzil, Kathleen (PLOS One, 2018-02-21)By analyzing publicly available surveillance data from 2011±2016, we produced countryspecific estimates of seasonal influenza activity for 118 countries in the six World Health Organization regions. Overall, the average country influenza activity period was 4.7 months. Our analysis characterized 100 countries (85%) with one influenza peak season, 13 (11%) with two influenza peak seasons, and five (4%) with year-round influenza activity. Surveillance data were limited for many countries. These data provide national estimates of influenza activity, which may guide planning for influenza vaccination implementation, program timing and duration, and policy development.
-
Data and product needs for influenza immunization programs in low- and middle-income countries: Rationale and main conclusions of the WHO preferred product characteristics for next-generation influenza vaccinesNeuzil, Kathleen; Bresee, Joseph; Hoz, Fernando de la; Johansen, Kari; Karron, Ruth A.; Krishnan, Anand; Madhi, Shabir A.; Mangtani, Punam; Spiro, David J.; Ortiz, Justin R. (2017-08)In 2017, WHO convened a working group of global experts to develop the Preferred Product Characteristics (PPC) for Next-Generation Influenza Vaccines. PPCs are intended to encourage innovation in vaccine development. They describe WHO preferences for parameters of vaccines, in particular their indications, target groups, implementation strategies, and clinical data needed for assessment of safety and efficacy. PPCs are shaped by the global unmet public health need in a priority disease area for which WHO encourages vaccine development. These preferences reflect WHO’s mandate to promote the development of vaccines with high public health impact and suitability in Low- and Middle-Income Countries (LMIC). The target audience is all entities intending to develop or to achieve widespread adoption of a specific influenza vaccine product in these settings. The working group determined that existing influenza vaccines are not well suited for LMIC use. While many developed country manufactures and research funders prioritize influenza vaccine products for use in adults and the elderly, most LMICs do not have sufficiently strong health systems to deliver vaccines to these groups. Policy makers from LMICs are expected to place higher value on vaccines indicated for prevention of severe illness, however the clinical development of influenza vaccines focuses on demonstrating prevention of any influenza illness. Many influenza vaccine products do not meet WHO standards for programmatic suitability of vaccines, which introduces challenges when vaccines are used in low-resource settings. And finally, current vaccines do not integrate well with routine immunization programs in LMICs, given age of vaccine licensure, arbitrary expiration dates timed for temperate country markets, and the need for year-round immunization in countries with prolonged influenza seasonality. While all interested parties should refer to the full PPC document for details, in this article we highlight data needs for new influenza vaccines to better demonstrate the value proposition in LMICs.